Home
IVVD
IVVD News

Latest Invivyd Inc. (IVVD) News on August 24, 2025

MT Newswires

2 months ago

Invivyd Says Study Shows VYD2311 Well Tolerated as COVID-19 Drug Candidate

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

GlobeNewswire

2 months ago

Invivyd Announces Positive Full Phase 1/2 Clinical Data for VYD2311, a Next Generation COVID-19 Monoclonal Antibody for Potential Use as a Non-Vaccine Preventative and for Treatment of Active Infection

COVID’s remaining biotech contenders navigate a dwindling market

Pharma Voice

3 months ago

COVID’s remaining biotech contenders navigate a dwindling market

Ulta Stock Jumps as Beauty Product Spending Continues

Investopedia

3 months ago

Ulta Stock Jumps as Beauty Product Spending Continues

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

GlobeNewswire

3 months ago

Drone Light Show Market to Soar to $5 Billion by 2034, Fueled by 13% CAGR and Rising Demand for Innovative Entertainment | Exactitude Consultancy

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

GlobeNewswire

3 months ago

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

Northrop Grumman Raises $1 Billion Via Debt

Benzinga

3 months ago

Northrop Grumman Raises $1 Billion Via Debt

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

GlobeNewswire

3 months ago

Spinosad Active Ingredient Market Set for Steady Growth, Driven by Sustainable Farming Trends | Exactitude Consultancy

Newsfile

3 months ago

Max Resource Corp. Announces Participation in THE Mining Investment Event, Quebec City, June 3-5, 2025

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

GlobeNewswire

3 months ago

TEN, Ltd. Announces Date for the First Quarter 2025 Results, Conference Call and Webcast

The York Water Company Files a Rate Request Based on $145 Million in Investment

GlobeNewswire

3 months ago

The York Water Company Files a Rate Request Based on $145 Million in Investment

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

Insider Monkey

3 months ago

H.C. Wainwright Lowers Invivyd (IVVD) PT to $5 Amid Q1 2025 Revenue Shortfall

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

GlobeNewswire

3 months ago

Invivyd Announces Publication of Landmark CANOPY Phase 3 PEMGARDA® (pemivibart) Clinical Trial; Results Underscore Strong Efficacy of Monoclonal Antibodies in Preventing COVID-19 in a Modern U.S. Population Against Relevant, Immune-Evasive SARS-CoV-2 Virus

MT Newswires

3 months ago

Invivyd's Pemgarda Added to NCCN Guidelines in Oncology for B-Cell Lymphomas

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

GlobeNewswire

3 months ago

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

GlobeNewswire

3 months ago

Invivyd Commends FDA Focus on Contemporary Evidence In Evaluating Medical Interventions To Prevent COVID-19

GuruFocus.com

3 months ago

Invivyd Inc (IVVD) Q1 2025 Earnings Call Highlights: Strategic Shifts and Financial Discipline ...

Thomson Reuters StreetEvents

3 months ago

Q1 2025 Invivyd Inc Earnings Call

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Zacks

3 months ago

Invivyd, Inc. (IVVD) Reports Q1 Loss, Lags Revenue Estimates

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

GlobeNewswire

3 months ago

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings

GuruFocus.com

3 months ago

What To Expect From Invivyd Inc (IVVD) Q1 2025 Earnings

MT Newswires

3 months ago

Invivyd Urges US FDA to Focus on Monoclonal Antibodies for COVID-19 Prevention, Re-Assess Vaccine Efficacy

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

GlobeNewswire

3 months ago

Invivyd Files Citizen Petition Urging FDA to Focus on Monoclonal Antibodies For Endemic-Virus-Era COVID-19 Prevention, and to Re-Assess COVID-19 Vaccine Efficacy

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

GlobeNewswire

3 months ago

Invivyd to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

GlobeNewswire

4 months ago

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

What's Going On With Invivyd Stock On Monday?

Benzinga

4 months ago

What's Going On With Invivyd Stock On Monday?

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

GlobeNewswire

4 months ago

Invivyd Announces $30M Non-dilutive Loan Facility with Silicon Valley Bank

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

GlobeNewswire

5 months ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates

Zacks

5 months ago

Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

GlobeNewswire

5 months ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?

Zacks

5 months ago

Are Investors Undervaluing Invivyd, Inc. (IVVD) Right Now?

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

GlobeNewswire

6 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody

Simply Wall St.

6 months ago

Invivyd (NasdaqGM:IVVD) Jumps 163% After Promising Phase 1/2 Trial Results For COVID-19 Antibody

Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025

Insider Monkey

6 months ago

Why Invivyd, Inc. (IVVD) is Skyrocketing So Far in 2025

Adagio Medical cuts workforce and pauses cryo catheter launch in EU

Medical Device Network

6 months ago

Adagio Medical cuts workforce and pauses cryo catheter launch in EU

The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine

Zacks

6 months ago

The Zacks Analyst Blog Highlights INVIVYD, 21Vianet, FuboTV, Noodles and Digital Turbine

MT Newswires

6 months ago

Sector Update: Health Care Stocks Gain Monday Afternoon

5 Stocks That More Than Doubled Halfway Through Q1

Zacks

6 months ago

5 Stocks That More Than Doubled Halfway Through Q1

MT Newswires

6 months ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

MT Newswires

6 months ago

Sector Update: Health Care

MT Newswires

6 months ago

Invivyd's Request to Treat Covid-19 Patients With Pemgarda Rejected by US FDA

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

GlobeNewswire

6 months ago

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far

Insider Monkey

6 months ago

Why Invivyd, Inc. (IVVD) Is Soaring This Year So Far

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

GlobeNewswire

6 months ago

Invivyd to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025

Exploring High Growth Tech Stocks in the United States

Simply Wall St.

7 months ago

Exploring High Growth Tech Stocks in the United States

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

GlobeNewswire

7 months ago

Invivyd Announces Partnership with Pro Football Coach Jim Harbaugh to Elevate Awareness and Ongoing Impact of COVID-19: Common, Not A Cold

MT Newswires

7 months ago

Invivyd Shares Soar Premarket After Tripling Monday Following Initial Results From COVID-19 Vaccination Alternative

Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025

Insider Monkey

7 months ago

Why Invivyd Inc (IVVD) Is Skyrocketing So Far In 2025

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

GlobeNewswire

7 months ago

Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

GlobeNewswire

7 months ago

Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability

We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon

Simply Wall St.

7 months ago

We Might See A Profit From Invivyd, Inc. (NASDAQ:IVVD) Soon

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

GlobeNewswire

7 months ago

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients

What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?

Benzinga

7 months ago

What's Going On With COVID-19 Antibody Developer Invivyd Stock On Friday?

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

GlobeNewswire

7 months ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC

Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media?

Insider Monkey

8 months ago

Why Invivyd, Inc. (IVVD) Is Among the Best Penny Stocks to Invest In According to Media?

Adagio Medical announces Todd Usen as new CEO and director

Medical Device Network

8 months ago

Adagio Medical announces Todd Usen as new CEO and director

MT Newswires

8 months ago

Adagio Medical Appoints Todd Usen as CEO

Thomson Reuters StreetEvents

9 months ago

Q3 2024 Invivyd Inc Earnings Call

GuruFocus.com

9 months ago

Invivyd Inc (IVVD) Q3 2024 Earnings Call Highlights: Strong Revenue and Strategic Growth Amidst ...

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates

Zacks

9 months ago

Invivyd, Inc. (IVVD) Reports Q3 Loss, Misses Revenue Estimates

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

9 months ago

Invivyd Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

GlobeNewswire

9 months ago

Invivyd Announces New England Journal of Medicine Publishes Letter to the Editor Highlighting Immunobridging Pathway Leading to PEMGARDA™ (pemivibart) Emergency Use Authorization; Comments on Adjacent Third-Party Letter to the Editor

Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect

GuruFocus.com

9 months ago

Invivyd Inc (IVVD) Q3 2024 Earnings Report Preview: What to Expect

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

GlobeNewswire

9 months ago

Invivyd Announces Preprints Conveying CANOPY Phase 3 Clinical Trial Data Including Long-Term Protection Versus Recent JN.1 Sublineages at Low Residual Titers, and Describing a Novel Approach for Predicting Monoclonal Antibody Activity Were Uploaded to MedRxiv and BioRxiv, Respectively

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

GlobeNewswire

10 months ago

Invivyd to Participate in the Guggenheim Securities Healthcare Innovation Conference

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

GlobeNewswire

10 months ago

Invivyd to Host Third Quarter 2024 Financial Results and Corporate Update Conference Call on November 14, 2024

MT Newswires

10 months ago

Invivyd Shares Fall After Revenue Guidance Withdrawal

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

GlobeNewswire

10 months ago

Invivyd Reports Preliminary Third Quarter 2024 Results, Withdraws Prior Financial Guidance, and Targets Near-Term Profitability

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

GlobeNewswire

10 months ago

Invivyd Phase 3 Long-Term Exploratory Clinical Efficacy Data Shows PEMGARDA™ (pemivibart) Provided Substantial Protection from Symptomatic COVID-19 Versus Placebo Over Six Months of Follow-Up, With No Additional Doses, In Immunocompetent Participants

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

GlobeNewswire

10 months ago

Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

GlobeNewswire

a year ago

Invivyd Announces U.S. FDA Has Updated the PEMGARDA™ EUA Fact Sheet with Accurate SARS-CoV-2 Variant Susceptibility and PEMGARDA Activity Data

MT Newswires

a year ago

Invivyd Provides Virology Data Supporting Pemivibart's Effectiveness Against Current SARS-CoV-2 Variants

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

GlobeNewswire

a year ago

Invivyd Provides Detailed Virology Data and Analysis of SARS-CoV-2 Structural Biology Predicting Anticipated Neutralization Activity for PEMGARDA™ (pemivibart)

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Simply Wall St.

a year ago

We're Keeping An Eye On Invivyd's (NASDAQ:IVVD) Cash Burn Rate

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

GlobeNewswire

a year ago

Invivyd at the Ready for Upcoming Respiratory Virus Season with PEMGARDA™ (pemivibart) to Help Protect Vulnerable Immunocompromised Persons from COVID-19

Invivyd to Participate in Upcoming Investor Conferences

GlobeNewswire

a year ago

Invivyd to Participate in Upcoming Investor Conferences

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

GlobeNewswire

a year ago

Invivyd Doses First Participants in Phase 1 Clinical Trial of VYD2311, a Next Generation Monoclonal Antibody Candidate for COVID-19, Building on the Success of PEMGARDA™

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

GlobeNewswire

a year ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest

MT Newswires

a year ago

Invivyd's Covid-19 Antibody Shows 84% Risk Reduction in Phase 3 Trial; Shares Fall

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

GlobeNewswire

a year ago

Invivyd Announces PEMGARDA™ (pemivibart) Demonstrated 84% Relative Risk Reduction in Symptomatic COVID-19 Compared to Placebo in an Exploratory Analysis from Ongoing CANOPY Phase 3 Clinical Trial

Thomson Reuters StreetEvents

a year ago

Q2 2024 Invivyd Inc Earnings Call

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Zacks

a year ago

Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

a year ago

Invivyd Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

GlobeNewswire

a year ago

Invivyd to Host Conference Call Discussing Second Quarter 2024 Financial Results and Business Highlights

MT Newswires

a year ago

Invivyd Joining Russell 2000, 3000 Indexes

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

GlobeNewswire

a year ago

Invivyd Announces its Addition to the Russell 2000® and Russell 3000® Indexes

Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future

Simply Wall St.

a year ago

Invivyd, Inc. (NASDAQ:IVVD) Is Expected To Breakeven In The Near Future

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

GlobeNewswire

a year ago

Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants

Invivyd to Participate at the Jefferies Global Healthcare Conference

GlobeNewswire

a year ago

Invivyd to Participate at the Jefferies Global Healthcare Conference

MT Newswires

a year ago

Invivyd in General Alignment With FDA on Emergency Use Authorization Pathway for Monoclonal Covid Antibodies

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

GlobeNewswire

a year ago

Invivyd Announces General Alignment with U.S. FDA on a Repeatable, Expedient Emergency Use Authorization Pathway for the Prevention and Treatment of Symptomatic COVID-19, Based on Compact Clinical Programs to Establish Safety and Immunobridging for Serial Monoclonal Antibodies

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

GlobeNewswire

a year ago

Invivyd Announces the Appointment of Timothy Lee as Chief Commercial Officer

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

GlobeNewswire

a year ago

Invivyd to Present Data at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and 2024 American Transplant Congress (ATC)

Invivyd Elects Two New Independent Members to its Board of Directors

GlobeNewswire

a year ago

Invivyd Elects Two New Independent Members to its Board of Directors

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

GlobeNewswire

a year ago

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Invivyd, Inc. (NASDAQ:IVVD) Q1 2024 Earnings Call Transcript

With 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interest

Simply Wall St.

a year ago

With 31% stake, Invivyd, Inc. (NASDAQ:IVVD) seems to have captured institutional investors' interest

GuruFocus.com

a year ago

Invivyd Inc (IVVD) Reports Q1 2024 Financial Results: A Detailed Analysis

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire

a year ago

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

GlobeNewswire

a year ago

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Share on Social Networks: